Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

Last year, we published an editorial in this journal, advocating the use of neoadjuvant treatment (NAT) in patients with breast cancer, especially for those bearing aggressive tumours (luminal B, triple-negative and HER2-positive subtypes).1 With the recent publication of important practice-changing data, we argue now that the use of NAT is the only ethical strategy for around one-third of women with early breast cancer.